(3S)-1,2,3,4-四氢-3-异喹啉甲胺 | 195832-21-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: (3S)-1,2,3,4-四氢-3-异喹啉甲胺
• 中文别名: 3(S)-氨基甲基-1,2,3,4-四氢异喹啉
• 英文名称: ((S)-1,2,3,4-tetrahydroisoquinolin-3-ylmethyl)amine
• 英文别名: (S)-(1,2,3,4-tetrahydroisoquinolin-3-yl)methanamine；[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanamine
• CAS: 195832-21-4
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.235
• InChiKey: QQDYNQIMTRERLH-JTQLQIEISA-N

物化性质

• 熔点：
  224-226 °C
• 沸点：
  294.8±20.0 °C(Predicted)
• 密度：
  1.033

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3S)-1,2,3,4-四氢-3-异喹啉甲胺 在 氢气 、 钯 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  特权生物可再生 Secologanin 基于多样性的伪天然生物碱合成：揭示新的神经保护和抗疟框架

  摘要：

  多样性获胜：secologanin 在自然界中的变色龙样行为确保了多种生物活性非天然生物碱的可持续、简单、高效和对映选择性的多样性导向合成。

  DOI：

  10.1002/cssc.202101868
• 作为产物：
  描述：

  (3S)-1,2,3,4-四氢-3-异喹啉甲酰胺 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 (3S)-1,2,3,4-四氢-3-异喹啉甲胺
  参考文献：
  名称：

  Synthesis of tetrahydroisoquinoline-diamine ligands and their application in asymmetric transfer hydrogenation

  摘要：

  The use of the tetrahydroisoquinoline scaffold is well documented in biologically active compounds. However, reports of the utilisation of tetrahydroisoquinoline compounds in asymmetric catalysis are limited. The synthesis of novel diamine ligands possessing the tetrahydroisoquinoline (tetrahydroisoquinoline) backbone and evaluation of their activity in the asymmetric transfer hydrogenation of acetophenone are presented. The diamine ligands in conjunction with i-PrOH as the hydrogen source and [RhCl2(Cp*)](2) as the metal precursor proved to be the most effective of the tetrahydroisoquinoline derivatives for this catalytic system. Water was found to have a profound influence on the enantioselectivity of the reaction. Optimisation of the amount water, i-PrOH and catalytic loading content rendered the best result of 70% enantioselectivity for the (S)-1-phenylethanol isomer product. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2010.04.017

文献信息

• Substituted indolizine-like compounds and methods of use
  申请人：——

  公开号：US20030195221A1

  公开（公告）日：2003-10-16

  Selected novel substituted indolizine-like compounds are effective for treatment of diseases, such as TNF-&agr;, IL-1&bgr;, IL-6 and/or IL-8 mediated diseases, and other maladies, such as cancer, pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for treatment of diseases and other maladies or conditions involving inflammation, cancer, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的类似吲哚啉的化合物对治疗疾病，如TNF-α、IL-1β、IL-6和/或IL-8介导的疾病，以及其他疾病，如癌症、疼痛和糖尿病具有有效性。本发明涵盖了新型化合物、类似物、前药和其药用可接受盐、制药组合物以及治疗涉及炎症、癌症、疼痛、糖尿病等疾病和其他疾患或情况的方法。该发明还涉及制备此类化合物的方法，以及在此类过程中有用的中间体。
• Dpp-IV Inhibitors
  申请人：Edwards John Paul

  公开号：US20070265301A1

  公开（公告）日：2007-11-15

  The invention relates to compounds of formula (I), wherein Z, R 1-8 , n, A 1 , X 1 and X 2 have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  该发明涉及式（I）的化合物，其中Z、R1-8、n、A1、X1和X2的含义如描述和权利要求所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备这种化合物以及作为药物的生产和使用。
• SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS
  申请人：Borzilleri Robert M.

  公开号：US20140135318A1

  公开（公告）日：2014-05-15

  Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and Q and G are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bcl-2 family antiapoptotic proteins for the treatment of cancer; and pharmaceutical compositions comprising such compounds.

  本发明涉及式（I）的化合物或其药学上可接受的盐，其中：W、Q和G的定义如下。还公开了使用这些化合物作为Bcl-2家族抗凋亡蛋白的抑制剂用于治疗癌症的方法；以及包含这些化合物的药物组合物。
• Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists
  作者：Gretchen M. Schroeder、Donna Wei、Patrizia Banfi、Zhen-Wei Cai、Jonathan Lippy、Maria Menichincheri、Michele Modugno、Joseph Naglich、Becky Penhallow、Heidi L. Perez、John Sack、Robert J. Schmidt、Andrew Tebben、Chunhong Yan、Liping Zhang、Arturo Galvani、Louis J. Lombardo、Robert M. Borzilleri

  DOI：10.1016/j.bmcl.2012.04.106

  日期：2012.6

  5-Butyl-1,4-diphenyl pyrazole and 2-amino-5-chloro pyrimidine acylsulfonamides were developed as potent dual antagonists of Bcl-2 and Bcl-xL. Compounds were optimized for binding to the I88, L92, I95, and F99 pockets normally occupied by pro-apoptotic protein Bim. An X-ray crystal structure confirmed the proposed binding mode. Observation of cytochrome c release from isolated mitochondria in MV-411 cells provides further evidence of target inhibition. Compounds demonstrated submicromolar antiproliferative activity in Bcl-2/Bcl-xL dependent cell lines. (C) 2012 Elsevier Ltd. All rights reserved.
• SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE
  申请人：AMGEN INC.

  公开号：EP1042293B1

  公开（公告）日：2008-03-19